Apogee Therapeutics (APGE)

Executive Summary

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing next-generation biologics for inflammatory and immune diseases, including atopic dermatitis (AD), asthma, and COPD. The company's lead product candidate, APG777, is a half-life extended anti-IL-13 antibody designed to achieve best-in-class efficacy and dosing convenience. APG777 is currently in Phase 2 trials for moderate-to-severe AD (NCT06395948) and Phase 1 for asthma (NCT06920901). Additionally, Apogee is exploring a combination approach with APG990 (anti-IL-4Rα) and dupilumab in a Phase 1 AD trial (NCT07027527), aiming to disrupt the current standard of care. Founded in 2022 and publicly traded (NASDAQ: APGE), the company has rapidly advanced its pipeline, leveraging differentiated molecular design to improve upon existing therapies like dupilumab. With a valuation of approximately $6.5 billion and a strong focus on high unmet need indications, Apogee represents a compelling opportunity in the immunology space, though clinical data readouts remain key value drivers.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 asthma trial (APG777) initial data75% success
• H2 2026Phase 2 atopic dermatitis trial (APG777) top-line data60% success
• H1 2027Phase 1 combination trial (APG777 + APG990 + dupilumab) interim results70% success